Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 13, 2018

SELL
$39.35 - $97.37 $3.94 Million - $9.74 Million
-100,000 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$15.48 - $46.19 $1.55 Million - $4.62 Million
100,000
100,000 $4.5 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.35B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Foresite Capital Management Iii, LLC Portfolio

Follow Foresite Capital Management Iii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.